Business
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney diseaseJACKSON CENTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease
About this update from Halberd Corp.
[{"type":"image","alt":"Halberd Corp.","displaySize":"","headline":null,"caption":"Halberd Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":258,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/780742d3701b26fb80aa35c5b05a3b3e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E2XxnOWE_5TTfxWs0Q5PHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/780742d3701b26fb80aa35c5b05a3b3e","width":258,"height":100}},"lazy":false},{"type":"text","content":"Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease","length":105,"tagName":"p"},{"type":"text","content":"JACKSON CENTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease.","length":396,"tagName":"p"},{"type":"text","content":"We previously found that our patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. We recognize that it is important to satisfy FDA indications and advance other unforeseen and profitable indications as we continue to expand the potential use of our proprietary LDX formulation. Following is our recent experimentation with LDX beyond our previous successful program on PTSD/Suicidal Ideation.","length":596,"tagName":"p"},{"type":"text","content":"The Problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology","length":258,"tagName":"p"},{"type":"text","content":"Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers.","le...